Vaxart Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vaxart Inc 's ROA in the third quarter of 2026?
Vaxart Inc achieved a return on average assets (ROA) of 16.99 % in its third quarter of 2026, this is above VXRT's average return on assets of -32.97%.
Vaxart Inc assets over the 12 months ending in its third quarter of 2026 are valued at $171 million

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 45 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 230, from total ROA ranking in the second quarter of 2026 at 778.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-26.99 %	0.67 %	13.56 %	25.61 %	41.89 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	29	39	37	16	-51
Return On Assets (TTM)	16.99 %	20.85 %	20.07 %	9.1 %	-29.84 %
VXRT's Total Ranking	# 230	# 778	# 3766	# 3887	# 4023
Total Assets (TTM) in million	153	165	180	186	209
Seq. Total Assets Change	-7.63 %	-8.26 %	-3.24 %	-10.96 %	27.37 %
Seq. Net Income Change	-	-	-90.59 %	-	-

VXRT's 5 Years Annual ROA >> Back to VXRT Management Effectiveness >> Compare VXRT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 8
Sector	# 46
Overall	# 209

Return On Assets Statistics
High	Average	Low
20.85 %	-32.97 %	-79.98 %
(Jun 30 2026)		(Mar 31 2024)

Financial Statements
Vaxart Inc 's Assets	$ 153 million	VXRT's Balance sheet
Vaxart Inc 's Income	$ -18 million	Quarterly VXRT's Income Statement
VXRT's Income by Division		See VXRT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	25.61 %	114.51 %	-46.7 %	-38.34 %	42.57 %
Total Assets in million	186	148	69	130	210
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	16	-67	-82	-108	-70
Annual Return On Assets	8.77 %	-45.19 %	-119.4 %	-83.17 %	-33.54 %

VXRT's 5 Years Annual ROA >> Back to VXRT Management Effectiveness >> Compare VXRT ROA to its Competitors

Comment on VXRT's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 8.77 % compared to prior year, due to annual net income growth of % to $16.33 million, while value of Vaxart Inc 's overall assets grew just by 25.61 % to $186.08 million, compared to $186.08 a year before.

More Return On Assets Ratios
VXRT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VXRT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VXRT's Competitors
Subscribers only: Roa for Vaxart Inc 's Suppliers
Subscribers only: Return On Assets for VXRT's Customers

You may also want to know
VXRT's Roi	VXRT's Inventory Turnover Ratio	VXRT's Growth Rates	VXRT's Dividend Comparisons
	VXRT's Profitability Ratios	VXRT's Asset Turnover Ratio	VXRT's Dividend Growth
VXRT's Roe	VXRT's Valuation Ratios	VXRT's Financial Strength Ratios	VXRT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %

Date modified: 2026-11-06T09:29:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.